Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 235

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 7
Chunk 235
---
Item 7. Major Shareholders and Related Party Transactions

A. Major Shareholders

The following table and accompanying footnotes set forth, as of April 25, 2025, information regarding beneficial ownership of the ordinary shares by:

• each person, or group of affiliated persons, known by Innate to beneficially own more than 5% of the ordinary shares;

• each of the Leadership Team and Supervisory Board members individually; and

• all of the Executive Board and Supervisory Board members as a group.

Assuming that all of the ordinary shares represented by ADSs are held by residents of the United States, as of December 31, 2024, the Company estimates that approximately 4.7 million shares, or 5.67% of the outstanding ordinary shares were held of record by residents of the United States.

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including free shares that vest within 60 days of April 25, 2025 and options and warrants that are currently exercisable or exercisable within 60 days of April 25, 2025. Ordinary shares subject to free shares, options and warrants currently exercisable or exercisable within 60 days of April 25, 2025 are deemed to be outstanding for computing the percentage of ownership of the person holding these free shares, options or warrants and the percentage of ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*).

Except as indicated by the footnotes below, the Company believes, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all ordinary shares shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Innate Pharma S. A., 117, Avenue de Luminy - BP 30191, 13009 Marseille, France.

                                                                                                         Number of Ordinary Shares Beneficially Owned      Percentage of Ordinary Shares Beneficially Owned  
 ─────────────────────────────────